Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
The optimal treatment approach for pulmonary arterial hypertension in pediatric patients depends upon the severity and underlying etiology of the disease.
Older patients with pulmonary arterial hypertension may have lower pulmonary artery compliance and worse right ventricular performance compared with their younger counterparts.
Balloon pulmonary angioplasty and pulmonary vasodilators were both found to improve functional and hemodynamic outcomes in patients with inoperable chronic thromboembolic pulmonary hypertension.
Risk stratification for survival and time to clinical worsening in pulmonary arterial hypertension based on 2015 ESC/ERS guidelines was confirmed only in patients without comorbidities.
Overall survival in congenital heart disease-associated pulmonary hypertension has been shown to be significantly better than in idiopathic pulmonary arterial hypertension.
Kidney transplant recipients with pre-existing pulmonary hypertension had a 1.5-fold increased risk for death compared with recipients without the condition, a study found.
Balloon pulmonary angioplasty can improve quality of life in patients with chronic thromboembolic pulmonary hypertension mainly by improving “usual activities.”
